Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 3
2015 1
2016 3
2017 2
2018 1
2019 1
2020 3
2021 4
2022 8
2023 14
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS. Scordo M, et al. Among authors: ramakrishnan geethakumari p. JAMA Oncol. 2021 Jul 1;7(7):993-1003. doi: 10.1001/jamaoncol.2021.1074. JAMA Oncol. 2021. PMID: 33956047 Free PMC article.
PARP Inhibitors in Prostate Cancer.
Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK. Ramakrishnan Geethakumari P, et al. Curr Treat Options Oncol. 2017 Jun;18(6):37. doi: 10.1007/s11864-017-0480-2. Curr Treat Options Oncol. 2017. PMID: 28540598 Review.
An international real-world analysis of relapsed/refractory lymphoma occurring during pregnancy.
Farooq F, Brandt JS, Cardonick E, Polushkina E, Vose J, Ahmed S, Ramakrishnan Geethakumari P, Olszewski AJ, Yasin H, Farooq U, Hamad N, Lin Y, Maggen C, Fruscio R, Gziri MM, Steffensen KD, Amant F, Evens AM. Farooq F, et al. Among authors: ramakrishnan geethakumari p. Blood Adv. 2023 Sep 26;7(18):5480-5484. doi: 10.1182/bloodadvances.2023010090. Blood Adv. 2023. PMID: 37259563 Free PMC article. No abstract available.
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma.
Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Shah H, Mehta-Shah N, Geethakumari PR, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng L, Standifer N, Hewitt L, Enowtambong E, Shao W, Sharma S, Carlesso G, Moscow JA, Siu LL. Chavez JC, et al. Among authors: geethakumari pr. Clin Cancer Res. 2023 May 15;29(10):1869-1878. doi: 10.1158/1078-0432.CCR-22-2955. Clin Cancer Res. 2023. PMID: 36826995 Free PMC article.
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study.
Epperla N, Zhao Q, Karmali R, Torka P, Shea L, Oh TS, Anampa-Guzmán A, Reves H, Tavakkoli M, Greenwell IB, Hansinger E, Umyarova E, Annunzio K, Sawalha Y, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Grover NS, Olszewski AJ. Epperla N, et al. Among authors: geethakumari pr. Blood Adv. 2023 Sep 12;7(17):5038-5046. doi: 10.1182/bloodadvances.2023010133. Blood Adv. 2023. PMID: 37315169 Free PMC article.
Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy.
Mulgaonkar A, Udayakumar D, Yang Y, Harris S, Öz OK, Ramakrishnan Geethakumari P, Sun X. Mulgaonkar A, et al. Among authors: ramakrishnan geethakumari p. Front Med (Lausanne). 2023 Jun 27;10:1199146. doi: 10.3389/fmed.2023.1199146. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37441689 Free PMC article. Review.
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Epperla N, et al. Among authors: geethakumari pr. J Hematol Oncol. 2022 Jul 16;15(1):96. doi: 10.1186/s13045-022-01316-1. J Hematol Oncol. 2022. PMID: 35842643 Free PMC article.
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study.
Annunzio K, Grover NS, Welkie RL, Torka P, Watkins MP, Anampa-Guzmán A, Tavakkoli M, Oh TS, Reves H, Jones D, Hanel W, Christian B, Ramakrishnan Geethakumari P, Karmali R, Barta SK, Bartlett NL, Olszewski AJ, Epperla N. Annunzio K, et al. Among authors: ramakrishnan geethakumari p. Blood Adv. 2023 Nov 28;7(22):6839-6843. doi: 10.1182/bloodadvances.2023011288. Blood Adv. 2023. PMID: 37792806 Free PMC article. No abstract available.
39 results